Please try another search
For the nine months ended 30 September 2011, LotusPharmaceuticals Inc revenues decreased 3% to $50.7M. Netincome applicable to common stockholders decreased 71% to$5.2M. Revenues reflect Wholesale & Third PartyManufacturing & Examination segment remaining flat at$15.3M. Net income also reflects Research and developmentexpenses increase from $22K to $1.9M (expense).
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Total Revenue | 19.04 | 18.69 | 12.92 | 20.14 |
Gross Profit | 3.31 | 4.89 | 6.15 | 10.5 |
Operating Income | 1.27 | 1.79 | 2.25 | -4.5 |
Net Income | 1.25 | 1.77 | 2.24 | -3.53 |
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Total Assets | 120.16 | 114.49 | 107.75 | 103.18 |
Total Liabilities | 20.7 | 17.24 | 13.82 | 14.16 |
Total Equity | 99.45 | 97.25 | 93.93 | 89.02 |
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 10.57 | 6.65 | 3.56 | 26.78 |
Cash From Investing Activities | -11.78 | -7.13 | -3.6 | -29.45 |
Cash From Financing Activities | 0 | 0 | 0 | |
Net Change in Cash | -1.18 | -0.45 | -0.03 | -2.61 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review